All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: HNKL-0.2 (for 10mM×0.2ml)

Cat. No.: HNKL-25 (for 25mg)

Cat. No.: HNKL-100 (for 100mg)

Description

Honokiol stands out as a bioactive biphenolic phytochemical renowned for its potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer properties, achieved through its targeting of various signaling molecules. Notably, it inhibits Akt activation while enhancing ERK1/ERK2 phosphorylation. Moreover, its ability to traverse the blood-brain barrier amplifies its therapeutic potential.

Basic Information

• Aliases: -
• Source: Magnolia officinalis Rehd. et Wils.
• Compound type: Phenylpropanoids > Lignans > Other Lignans
• Chemical Formula: C₁₈H₁₈O₂
• Molecular Weight: 266.33
• CAS Number: 35354-74-6
• Purity: 98%, HPLC
• Solvent/Solubility: DMSO: ≥ 50 mg/ml (187.74 mM)
• Solution Preparation: Add 5mg to 1.88ml of DMSO, or alternatively, add 2.66mg to 1ml of DMSO, to prepare a 10mM solution.

Signaling Pathway

-

In Vitro Study

Honokiol demonstrates inhibitory effects on the growth of GBM cells at concentrations of 0, 12.5, 25, and 50 μM, inducing apoptosis with an approximate IC50 of 30 μM against DBTRG-05MG cells. This induction of apoptosis in GBM cells by honokiol is correlated with the downregulation of Rb protein, as well as the cleavage of PARP and Bcl-x (S/L). At a concentration of 50 μM, honokiol elevates the levels of autophagy markers in GBM cells. 

Furthermore, honokiol exhibits anticancer effects, with IC50 values against MDA-MB-231, MDA-MB-468, and MDA-MB-453 cell lines measured at 16.99 ± 1.28 μM, 15.94 ± 2.35 μM, and 20.11 ± 3.13 μM, respectively.

In clonogenic assays, honokiol at concentrations of 3 and 10 μM significantly inhibits spheroid number and size. Additionally, honokiol selectively inhibits washed human platelet aggregation induced by collagen at concentrations ranging from 0.1 to 1.0 μM, without affecting other agonists. Furthermore, at concentrations of 0.6 and 1.0 μM, honokiol concentration-dependently inhibits collagen-induced ATP release in washed human platelets.

Moreover, honokiol specifically inhibits platelet aggregation and the phosphorylation of Lyn, PLCγ2, and PKC when stimulated with convulxin. In addition, honokiol at concentrations of 5 and 10 μM significantly inhibits convulxin-stimulated MAPKs and Akt activation. Finally, honokiol at concentrations of 10 and 20 μM enhances ERK1/2 phosphorylation in a dose-dependent manner through CaMK II activation.

In Vivo Study

Honokiol-NM (40 mg/kg, orally administered) exhibits remarkable anticancer efficacy, resulting in significant alterations of PCNA, Cyclin D1, and cleaved caspase 3 expressions by 2.12-fold, 1.92-fold, and 1.68-fold, respectively, in the treated group.

Clinical Trial

N/A

Storage

Store at -20°C, effective for at least one year. Store solid powder at 4°C, effective for at least one month. If dissolved in a non-DMSO solvent, it is recommended to aliquot and store at -80°C, expected to be effective for up to six months.

Precautions

• This product may have a certain degree of toxicity to the human body. Please take appropriate precautions to avoid direct contact with the body or inhalation.
• This product is for scientific research use only by professionals and is not intended for clinical diagnosis or treatment, food, or pharmaceutical purposes. It should not be stored in ordinary residential areas.
• For your safety and health, please wear laboratory attire and disposable gloves while handling.

Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products                                       Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory